CooperVision has shared the results of several studies, including one demonstrating its dual-focus MiSight 1-day contact lenses’ (CLs’) suitability for high myopia.
Presenting at the 2023 British Contact Lens Association (BCLA) clinical conference, CooperVision shared Nguyen et al’s study, ‘Dual focus contact lenses deliver a myopia control signal to the retinas of highly myopic eyes’. Subjects with high myopia (-6.50D to -9.25D) were enrolled and fitted with single vision or MiSight 1-day lenses. Researchers reported MiSight delivered significant and consistent amounts of myopic defocus over a wide range of viewing distances, illustrating the potential for the lens’ use in this population, which has an exponentially greater risk for maculopathy and other adverse sequalae.
Describing it as the longest evaluation of soft-CL interventions for myopia, CooperVision also shared results of the study ‘Case series on myopia progression in children beyond a period of no treatment following three or six years of MiSight 1-day treatment’ (Logan and Jones). In the study, researchers examined young adults who had worn the CL as part of the six-year clinical trial then transitioned to a single-vision lens for the seventh year. (A subset whose refraction did not stabilise subsequently returned to MiSight 1 day wear for year eight.) Investigators found reinitiating MiSight treatment, even in patients’ late teens, resulted in either slowed or stopped myopia progression and axial elongation, with no reported issues in re-adapting to the dual-focus design.
